Ascendis Pharma to raise capital with convertible notes

Biotech firm Ascendis Pharma intends to offer convertible notes for a sum of USD 500m.

Photo: Kevin Grønnemann / MedWatch

Danish biotech firm Ascendis Pharma, which is listed in the US, wants to raise USD 500m by offering convertible notes, the company reports in a press release.

According to the company, the notes will mature in 2028 and are meant for ”qualified institutional buyers” pursuant to Securities and Exchange Commission (SEC) rules.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs